• Hepatocyte Tri-culture Platform– Led the Research phase of an all human hepatic tri-culture drug screening platform available in a high throughput screening (HTS) 96-well format, converted concept to prototype within 12 months– Consulted with key opinion leaders and literature for key design aspects and critical platform characterization required – Drafted documentation for the production, quality control, and instructions for use – Trained LifeNet Health personnel to establish and analyze all human tri-culture for internal alpha testing on the platform– Filed intellectual property (Serial #: 62/562, 127)– Authored poster for conference presentation (SOT 2019), and currently working on a manuscript for publication• Pancreatic Islet Cell Isolation– Co-led the establishment of a human islet cell isolation lab, developing and optimizing isolation, characterization, and shipping parameters and protocols in parallel within a team of four people– Established and performed islet quality assays and documentation to include islet counting, glucose stimulated-insulin secretion (GSIS) assay, immunocytochemical staining, flow cytometry, viability assay, and qRT-PCR– Automated the 3D islet viability assay (FDA/PI staining) re-purposing existing equipment and software which reduced the technician time from 8 hours per assay to 2 hours per donor– Prepared and/or assisted in the preparation of reports, and SOPs– Performed work in compliance with SOPs, GLP regulations, and company policies• Placenta ECM Validation for iPSC Culture– Lead the validation of a human placenta-based extra-cellular matrix (ECM) validation with both Induced pluripotent stem cells (iPSCs) and bone marrow stem cells (BM-MSCs)– Analyzed validation data sets and authored a manuscript for publication– Executed BM‐MSC proliferation and differentiation on HuGentra to support stem cell application

• Generated a 3D in vitro osteogenesis platform by encapsulating bone particles in a human placenta based and commercially available ECM• Optimized protocols for the construction of 3D bioprinted constructs from fibroblasts, osteoblasts, mesenchymal stem cells, hepatocytes, and hepatocyte carcinoma cell with the Cyfuse 3D Bioprinter• Tested the feasibility of downstream in vitro platform development, identifying and quantifying biomarkers on 3D printed constructs via molecular, histologic, and functional assays• Designed, planned, and executed validation studies for the differentiation of iPSCs into three germ layers on a humanized placenta derived ECM• Isolated primary human cells from multiple tissue types and characterized the cells based on various molecular and genomic biomarker assays for transfer to a production setting • Performed work in compliance with SOPs, GLP regulations, and company policies• Established in-house hepatocyte culture system– Trained with hepatocyte specialists’ team at LifeNet Health’s Research Triangle Park, North Carolina branch on general hepatocyte culture and introduced hepatocyte culture to the Virginia Beach campus– Setup assays for hepatocyte general characterization, such as morphology and bioactivity, by measuring the level of CyP450

• Independently planned and carried out a variety of experiments for the optimization and characterization of various products within a team of 20+ researchers• Maintained pluripotent stem cells, performed osteogenic, chondrogenic, and adipogenic differentiation assays• Performed differentiation assays and downstream analysis through qRT-PCR, flow cytometry, and staining assays; results are published in Preferential Lineage-Specific Differentiation of Osteoblast-Derived Induced Pluripotent Stem Cells into Osteoprogenitors, Stem Cells International (2017)• Developed osteoinductivity assays of demineralized bone matrices (DBM) though protein and functional analysis, including cell-based alkaline phosphatase assay and ELISAs (p-SMAD, BMPs) for In Vitro correlation data sets • Performed cytotoxicity assay (ISO 10993-5) – data was used to optimize cartilage graft decellularization • Assessed the cellular metabolic activity of Theraskin split thickness frozen skin grafts; data was used for publication• Isolated and analyzed cells from placenta membranes using protocols from literature and a custom viability assay• Managed the maintenance and calibration of equipment within a lab of 13 cross-functional areas with more than 30 lab users, facilitating communication with outside vendors, facilities, and lab users to ensure proper equipment scheduling, calibration and maintenance, and documentation• Drafted and implemented lab safety SOPs together with lab safety officer for new lab facility containing more than 13 cross-functional lab suites to ensure safety of the staff and proper aseptic and sterile work environments

• Optimized the ViviGenTM Cellular Bone Matrix processing, shipping, quality control, and production transfer as a part of a 5-person research team• Researched technical problems through literature reviews, developed assays, and optimized culture and shipping parameters in parallel within a well-planned timeline• Developed and optimized the cell isolation and culture conditions for the osteoblasts cells in ViviGen, a cryopreserved, viable bone graft• Characterized bone cells from the ViviGen product via functional and molecular assays generating data sets for white papers • Isolated and provided lymphocytes for the mixed lymphocyte reaction assay – immunocompatibility testing of the bone cells • Assisted in conducting the mixed lymphocyte reaction assay with donor lymphocytes and isolated bone cells• Optimized the ViviGenTM Cellular Bone Matrix processing, shipping, quality control, and production transfer as a part of a 5-person research team• Researched technical problems through literature reviews, developed assays, and optimized culture and shipping parameters in parallel within a well-planned timeline• Developed and optimized the cell isolation and culture conditions for the osteoblasts cells in ViviGen, a cryopreserved, viable bone graft• Characterized bone cells from the ViviGen product via functional and molecular assays generating data sets for white papers • Isolated and provided lymphocytes for the mixed lymphocyte reaction assay – immunocompatibility testing of the bone cells • Assisted in conducting the mixed lymphocyte reaction assay with donor lymphocytes and isolated bone cells• Developed and transferred a quantitative viable cell assay to Quality Control department for the analysis and lot release of ViviGen Cellular Bone Matrix clinical grafts• Prepared and/or assisted in the preparation of study protocols, reports, and SOPs • Performed work in compliance with SOPs, GLP regulations, and company policies